TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI®  ( ublituximab-xiiy )  in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting - TG Therapeutics  ( NASDAQ:TGTX )